Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection

NCT02633553 · tracked via the Priya Life Science China tracker

Sponsor

Fudan University

Phase

Not applicable

Started

2018-01-10

Last updated

2026-04-24

Condition(s) studied

Thymoma

Investigational drug(s) / intervention(s)

adjuvant radiotherapy

adjuvant radiotherapy: 50Gy/25Fx

Study summary

This study is designed to investigate whether adjuvant radiotherapy after complete resection has a better survival for stage II or III thymoma.

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: 18\~75 years old; Eastern Cooperative Oncology Group performance status of 0 to 2; Pathologically confirmed masaoka stage II or III thymoma; Have adequate bone marrow, hepatic, and renal function; Patients receive complete resection within 3 months; Written informed consent. Exclusion Criteria: Patients with distant metastases; Patients underwent radiotherapy or chemotherapy; Patients who have malignancy history excluding carcinoma in situ of cervix in the previous five years; Active clinical pulmonary infection; Pregnant or nursing.

Primary outcome measure(s)

DFS (Disease free survival) — 5 years
from registration to disease progression or death.

Trial sites (1)

Facility	City	Region	Status
Kailiang Wu	Shanghai	Shanghai Municipality	Recruiting

More Fudan University trials in China

Real-World Study of Young Patients With Solid Tumors in China Recruiting

Preservation Vs. Dissection of No. 253 Lymph Nodes of Robotic Resection for Mid/Low Rectal Cancer Starting soon

Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases Active, not recruiting

Multi-mode Ablation and Molecular Imaging Multi-omics Study for Digestive-Origin Malignant Liver Tumors Active, not recruiting

ELobectomy for NSCLC by VATS Versus Thoracotomy (ECTOP-1007) Recruiting

Other trials for the same condition

Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma Recruiting

Robot-assisted vs VATS for Thymoma Recruiting

Hypofractionated Radiotherapy for Thymic Epithelial Tumors Recruiting

Electrocautery Resection Combined With HITHOC for Thymic Epithelial Tumors With Pleural Metastasis Starting soon

Hypofractionated Adjuvant Radiotherapy for Thymic Epithelial Tumors Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02633553 on ClinicalTrials.gov ↗ ← All trials in China